Merck has entered a multi-year collaboration with Tempus AI to accelerate precision medicine by applying Tempus’ large de-identified multimodal dataset and high-performance GPU-driven Lens Platform. The agreement focuses on enhancing discovery and development of novel oncology biomarkers to inform targeted therapy development.

The partnership aims to identify mechanisms of cancer cell resistance and novel biomarkers across Merck’s oncology and broader therapeutic portfolios. By integrating AI-driven analyses, Merck expects to streamline its biomarker pipeline and potentially improve patient stratification in clinical trials.

Keytruda accounted for approximately 55% of Merck’s pharmaceutical sales in 2025, reinforcing its position as the company’s leading revenue driver. This blockbuster PD-1 inhibitor has consistently fueled top-line growth and supports ongoing investments in Merck’s oncology pipeline.